Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allogeneic Stem Cell Transplant for Hematologic Disorders
NCT00636909Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jul 1999
- Primary completion
- Mar 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of cyclophosphamide, fludarabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS), sponsored by Beth Israel Deaconess Medical Center. Started Jul 1999; status: completed.
02
Drugs
cyclophosphamidefludarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT00636909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636909.